JMP Securities reissued their market outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a report published on Friday, Benzinga reports. JMP Securities currently has a $7.00 price target on the stock.
Several other equities research analysts also recently weighed in on ELEV. Stephens started coverage on shares of Elevation Oncology in a research report on Tuesday, May 14th. They set an overweight rating and a $8.00 price target for the company. Wedbush reaffirmed an outperform rating and issued a $8.00 target price on shares of Elevation Oncology in a research report on Friday, May 3rd. HC Wainwright reaffirmed a buy rating and issued a $6.00 target price on shares of Elevation Oncology in a research report on Tuesday, April 9th. Finally, Piper Sandler started coverage on shares of Elevation Oncology in a research report on Friday, May 31st. They issued an overweight rating and a $10.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of Buy and an average price target of $7.80.
View Our Latest Analysis on Elevation Oncology
Elevation Oncology Stock Performance
Elevation Oncology (NASDAQ:ELEV – Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.21) by ($0.02). Analysts predict that Elevation Oncology will post -0.92 EPS for the current fiscal year.
Institutional Investors Weigh In On Elevation Oncology
A number of hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new stake in shares of Elevation Oncology during the 1st quarter valued at $63,000. Vanguard Group Inc. grew its position in shares of Elevation Oncology by 30.8% during the 1st quarter. Vanguard Group Inc. now owns 1,532,045 shares of the company’s stock valued at $7,859,000 after acquiring an additional 360,799 shares during the period. Affinity Asset Advisors LLC bought a new stake in shares of Elevation Oncology during the 1st quarter valued at $6,509,000. Artal Group S.A. bought a new stake in shares of Elevation Oncology during the 1st quarter valued at $7,762,000. Finally, Darwin Global Management Ltd. bought a new stake in shares of Elevation Oncology during the 1st quarter valued at $11,968,000. Institutional investors own 83.70% of the company’s stock.
About Elevation Oncology
Elevation Oncology, Inc, an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target.
Featured Stories
- Five stocks we like better than Elevation Oncology
- Election Stocks: How Elections Affect the Stock Market
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- 3 Must-Buy Warren Buffett Stocks for Volatile Times
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- How to Read Stock Charts for Beginners
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Elevation Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elevation Oncology and related companies with MarketBeat.com's FREE daily email newsletter.